Researchers report a possible new marker in infertility assessment

Loss of the X chromosome in blood cells may be associated with a reduced chance of natural pregnancy, according to a study led by researchers at Osaka Metropolitan University. The work points to a little-discussed age-related genetic change in women and suggests it could become useful alongside existing fertility markers.

The study compared white blood cells from women aged 20 to 45, including 123 who had conceived naturally and 381 who had not. The researchers found that women with infertility had a significantly higher proportion of cells showing loss of the X chromosome, or LOX. They also reported that when the share of LOX cells exceeded about 0.9%, the likelihood of natural pregnancy decreased.

The findings were published in Reproductive BioMedicine Online, and the supplied source describes the paper as peer reviewed.

A less familiar counterpart to loss of the Y chromosome

Most people learn a simplified model of sex chromosomes in which women typically have two X chromosomes and men have one X and one Y. What is less widely recognized is that these chromosomes can be lost in some blood cells as people age. In men, loss of the Y chromosome has already been linked to several diseases, including Alzheimer’s disease, diabetes mellitus, and heart disease. In women, loss of the X chromosome has been connected in previous research to conditions such as acute myeloid leukemia and pneumonia.

Its reproductive role, however, has remained much less clear. That gap is what the Osaka Metropolitan University team set out to examine. By focusing on women who had and had not conceived naturally, the researchers asked whether LOX might correlate with reduced fertility in a measurable way.

The answer, based on this dataset, appears to be yes. The infertility group showed a higher proportion of LOX cells, suggesting that this chromosomal change may be associated with difficulty conceiving without treatment.

Why the 0.9% threshold stands out

The reported threshold is one of the study’s most concrete findings. According to the supplied summary, once LOX in white blood cells rose above roughly 0.9%, the chance of achieving natural pregnancy declined. That does not mean LOX alone determines fertility outcomes, and the study summary does not describe it as a standalone diagnostic test. But it does point to a measurable level at which the association became more pronounced.

That matters because infertility evaluation often relies on combining multiple indicators rather than searching for one definitive answer. A marker that captures a dimension of reproductive aging or genetic change not reflected in standard tests could improve how clinicians estimate prospects for natural conception.

It may also help explain cases in which common fertility indicators do not fully align with outcomes. The study’s authors suggest LOX could offer information that current approaches miss.

How it compares with anti-Mullerian hormone

The researchers also examined anti-Mullerian hormone, or AMH, which is commonly used as a marker of ovarian reserve. In the supplied report, the team found that AMH levels were not associated with the LOX measurements used in the study.

That separation is important. If AMH and LOX are not tracking the same biological signal, they may provide complementary information rather than redundant measurements. First author Taiki Kikuchi said combining AMH with LOX analysis could allow more accurate prediction of whether natural pregnancy is possible.

That framing is more cautious and more useful than treating the study as a breakthrough test on its own. The source does not claim LOX replaces established fertility assessment tools. Instead, it suggests an additional layer of insight that might support earlier or better-targeted decisions.

Potential implications for fertility treatment timing

One of the study’s more practical implications concerns timing. Kikuchi said that measuring LOX in people experiencing infertility could help determine whether natural pregnancy is likely or whether fertility treatment, including in vitro fertilization, should begin earlier.

That is a clinically relevant idea because delays in treatment can matter, especially when age-related biological changes are already underway. If LOX proves reliable in further research, it could help distinguish between patients who may reasonably continue trying to conceive naturally and those who would benefit from faster escalation to assisted reproduction.

Still, the supplied report does not establish clinical guidelines, intervention thresholds, or treatment outcomes based on LOX-informed decisions. Those would require additional validation and likely larger studies.

What the findings do and do not prove

The main conclusion supported by the supplied source is that LOX in white blood cells is associated with infertility and a lower likelihood of natural pregnancy above a reported threshold. That is an important result, but it should be read as an association rather than a proof of causation based on the information provided.

The report does not say that LOX directly causes infertility, nor does it show whether reducing LOX would change reproductive outcomes. It also does not indicate how broadly the finding generalizes across populations outside the studied group.

Even so, the study adds a potentially valuable concept to reproductive medicine. Fertility assessment has long relied on hormonal, anatomical, and timing-based measures. A chromosomal-loss signal detectable in blood could expand that toolkit in a way that is biologically distinct from ovarian reserve markers.

  • Researchers compared women aged 20 to 45 who had conceived naturally with women who had not.
  • Women with infertility showed a higher proportion of blood cells with loss of the X chromosome.
  • A LOX proportion above about 0.9% was associated with lower odds of natural pregnancy.
  • LOX was not associated with AMH, suggesting it may provide different information from ovarian reserve testing.

If future studies confirm the result, LOX could become part of a more nuanced fertility evaluation strategy. For now, the study’s contribution is to identify a measurable genetic signal that appears linked to natural conception odds and that may eventually help shape when and how infertility treatment begins.

This article is based on reporting by Medical Xpress. Read the original article.